Figure 2.

Alemtuzumab concentration levels in the accumulation phase from this study compared with data reported by Hale.¹² Serum levels from this study were compared with alemtuzumab levels after IV administration and after sc administration, reported by Hale:¹² (●) indicates concentration from this study during sc administration; (□), concentration of 1.0 μg/mL reached after a median of eight days, after IV administration reported by Hale;¹² (ρ), concentration of 1.0 μg/mL reached after a median of 40 days, after sc administration reported by Hale.¹²